AasiyaMatinMD

Hematology • Rochester, MN

Physician

Join to view full profile

Are you Dr. Matin?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 31 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
200 1st St SW
Rochester, MN 55905
Phone+1 507-284-2511

Summary

Dr. Aasiya Matin, MD is a hematologist in Rochester, Minnesota. She is currently licensed to practice medicine in Minnesota, Michigan, and Arkansas. She is affiliated with UAMS Medical Center, Karmanos Cancer Center, and DMC Harper University Hospital.

Education & Training

Detroit Medical Center/Wayne State UniversityResidency, Internal Medicine, 2010 - 2013
Baba Raghav Das Medical CollegeClass of 1998

Certifications & Licensure

MI State Medical License 2021 - 2027
MN State Medical License 2019 - 2025
AR State Medical License 2013 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Therapeutic Research in Multiple Myeloma Start of enrollment: 2003 Aug 01
Completed
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy Start of enrollment: 2009 Mar 01
Active, not recruiting
Phase 2
UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma Start of enrollment: 2010 Apr 01
Completed
Phase 3
UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma Start of enrollment: 2013 Apr 01
Completed
Phase 2
UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib Start of enrollment: 2015 Mar 01
Withdrawn
Phase 2
UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus Start of enrollment: 2015 Mar 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.
Naseema Gangat, Azeem Elbeih, Nour Ghosoun, Kristen McCullough, Fnu Aperna
American Journal of Hematology. 2024-12-13
1 citations
Pericardial Effusion as a Purported Manifestation of Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation.
Aasiya Matin, Byron H Smith, Abhishek Mangaonkar, Dustin J Duffy, Robert Wolf
Transplantation and Cellular Therapy. 2023-05-01
1 citations
Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant.
Aung M Tun, Yucai Wang, Aasiya Matin, David J Inwards, Thomas M Habermann
Hemasphere. 2023-04-01